Semaglutide, the blockbuster drug better known by brand names like Ozempic and Wegovy, has now shown significant promise in ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

How a commonly “silent disease” is driving urgency and novelty in the liver disease treatment paradigm and what can we hope for.

Key outcomes of all-cause mortality and portal hypertension complications are improved with SGLT2inhibitors, new research ...

Results showed that 62.9% of patients on Ozempic saw a reduction in liver inflammation, compared to 34.3% on placebo.

I. Posters Six posters have been accepted for presentation at EASL Congress mainly covering several of GENFIT’s assets positioned in ACLF and, including, GENFIT’s latest work on Real-World data in ...

A new study reveals that semaglutide, a common diabetes medication, may effectively treat fatty liver disease, offering hope ...

Semaglutide, a GLP-1 receptor agonist sold under brand names Wegovy and Ozempic, is approved for weight loss and blood sugar ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

In a significant medical breakthrough, researchers from King’s College London have found that semaglutide, a drug commonly ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine.

In the 10-Q report, 89bio detailed its progress in the development of pegozafermin, particularly in its Phase 3 clinical ...